An atypical form of AOA2 with myoclonus associated with mutations in SETX and AFG3L2 by Mancini, C et al.
Mancini et al. BMC Medical Genetics  (2015) 16:16 
DOI 10.1186/s12881-015-0159-0RESEARCH ARTICLE Open AccessAn atypical form of AOA2 with myoclonus
associated with mutations in SETX and AFG3L2
Cecilia Mancini1†, Laura Orsi2†, Yiran Guo3†, Jiankang Li4†, Yulan Chen4, Fengxiang Wang3, Lifeng Tian3,
Xuanzhu Liu4, Jianguo Zhang4, Hui Jiang4,5,6, Bruce Shike Nmezi7, Takashi Tatsuta8, Elisa Giorgio1,
Eleonora Di Gregorio9, Simona Cavalieri9, Elisa Pozzi1, Paolo Mortara2,10, Maria Marcella Caglio10,11,
Alessandro Balducci10,11, Lorenzo Pinessi2,10, Thomas Langer8,12, Quasar S Padiath7, Hakon Hakonarson3,13,14,
Xiuqing Zhang4,5,6 and Alfredo Brusco1,9*Abstract
Background: Hereditary ataxias are a heterogeneous group of neurodegenerative disorders, where exome
sequencing may become an important diagnostic tool to solve clinically or genetically complex cases.
Methods: We describe an Italian family in which three sisters were affected by ataxia with postural/intentional
myoclonus and involuntary movements at onset, which persisted during the disease. Oculomotor apraxia was
absent. Clinical and genetic data did not allow us to exclude autosomal dominant or recessive inheritance and
suggest a disease gene.
Results: Exome sequencing identified a homozygous c.6292C > T (p.Arg2098*) mutation in SETX and a
heterozygous c.346G > A (p.Gly116Arg) mutation in AFG3L2 shared by all three affected individuals. A fourth sister
(II.7) had subclinical myoclonic jerks at proximal upper limbs and perioral district, confirmed by electrophysiology,
and carried the p.Gly116Arg change. Three siblings were healthy.
Pathogenicity prediction and a yeast-functional assay suggested p.Gly116Arg impaired m-AAA (ATPases associated
with various cellular activities) complex function.
Conclusions: Exome sequencing is a powerful tool in identifying disease genes. We identified an atypical form of
Ataxia with Oculoapraxia type 2 (AOA2) with myoclonus at onset associated with the c.6292C > T (p.Arg2098*)
homozygous mutation. Because the same genotype was described in six cases from a Tunisian family with a typical
AOA2 without myoclonus, we speculate this latter feature is associated with a second mutated gene, namely
AFG3L2 (p.Gly116Arg variant).
We suggest that variant phenotypes may be due to the combined effect of different mutated genes associated to
ataxia or related disorders, that will become more apparent as the costs of exome sequencing progressively will
reduce, amplifying its diagnostics use, and meanwhile proposing significant challenges in the interpretation of the
data.
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The hereditary ataxias are a highly genetically heteroge-
neous group of disorders phenotypically characterized
by gait ataxia, incoordination of eye movements, speech,
and hand movements, and usually associated with cerebel-
lar atrophy. Autosomal dominant forms (Spinocerebellar
ataxia, SCA) typically have adult-onset; conversely auto-
somal recessive ataxias (Spinocerebellar ataxias autosomal
recessive, SCAR) usually have onset in childhood [1,2].
Genetic tests needed to define the subtype are often
long and laborious, due to the size of many ataxia genes
(e.g., SYNE1, SACS, ATM, and SETX).
As a possible alternative to the gene-by-gene mutation
screening, the application of Next Generation Sequen-
cing technologies (NGS), involving simultaneous analysis
of hundreds of selected exons or the entire sequencing
of human coding genes (exome) are increasingly being
used as a diagnostic tool, because of affordable costs and
the availability of efficient bioinformatics tools. This
approach becomes even more efficient in the case of a het-
erogeneous phenotype or unspecific clinical symptoms,
which may make difficult a correct genetic diagnosis.
Beyond the mutation detection which is important
to define a diagnosis for genetic counselling, futureFigure 1 Family tree, mutation analysis, and yeast functional assay. A
but clinical data from the father and the mother (died at 37 yrs) were incomp
the SETX gene show a homozygous region in the three affected individuals. S
c.6269C > T and AFG3L2 c.346G> A mutations are indicated below each sub
mutations with accompanying amino acid changes. C. Evolutionary conse
is conserved in all vertebrates analyzed. D. Yeast functional assay of p.Gly116A
human through to S. cerevisiae where both homo-oligomeric Yta12 (AFG3L2 o
subunits are present. These proteins can be substituted with the human orth
yeast cells (ΔΔ) the synthesis of mitochondrial-encoded respiratory chain subu
growing only on carbon fermentable source [Yeast extract Peptone and D
(Yeast extract Peptone and Glycerol: YPG). Δyta10Δyta12 yeast transfected
AFG3L2G116R is unable. The co-transfection of SPG7 and AFG3L2G116R rescuprenatal diagnosis and eventually therapy, exome ana-
lysis may also reveal unexpected findings, such as pos-
sible disease modifier genes [3].
In this study, we analyzed a single family with three
sisters affected by ataxia with an atypical postural and
intentional myoclonus. Exome sequencing revealed a
homozygous SETX gene mutation, and an unexpected
c.346G > A (p.Gly116Arg) variant in the AFG3L2 gene
-responsible of SCA28- predicted to alter protein func-
tion. Clinical re-evaluation of the patients confirmed
some typical feature of AOA2 and identified a fourth
sibling carrying p.Gly116Arg with initial signs of myo-
clonus, suggesting variants in AFG3L2 may be also asso-
ciated with myoclonus.
Methods
Study subjects
We identify three subjects from family ATA-2-TO (II.1,
II.2, II.3 in Figure 1) presented with unsteadiness and
difficulties in walking accompanied by a large spectrum
of involuntary movements. Due to the early death of the
mother and the unavailability of the father, we did not
initially ascertain the type of transmission. As an initial
workout, we excluded ataxias due to polyglutamine. ATA-2-TO family tree suggested an autosomal recessive transmission,
lete. Below the segregation of three microsatellite markers surrounding
ubject II.7 had subclinical myoclonus (see text). The presence of SETX
ject. B. Electropherograms of SETX c.6269C > T and AFG3L2 c.346G > A
rvation of glycine at position 116 in the AFG3L2 protein. The position
rg mutation [4] m-AAA proteases are evolutionarily highly conserved from
rthologue), and hetero-oligomeric Yta10 (SPG7 orthologue) - Yta12
ologues in order to study specific missense changes. In Δyta10Δyta12
nits is impaired and cells are unable to perform aerobic respiration,
extrose (glucose): YPD] [4-6] and not on a non-fermentable source
with human AFG3L2 is able to grow on YPG, whereas human
ed the phenotype.
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fetoprotein was available only at the end of the study.
Short Tandem Repeats (STR) typing excluded SCA14
and SACS loci.
To evaluate the possible consanguinity in family ATA-
2-TO, after mutation discovery, we studied the following
markers in the 9q34 region surrounding SETX: chr9_135.0
(5′-tgttatttgcactgggagga; 5′-agctcaatgtagctgttatttttct); chr
9_135.3 (5′-atgggatacatgcacacgttta; 5′-caatgcagctcacttgaaa
actta); D19S149 (5′-gattgacctgtgaatttgtacagc; 5′-tgttatgcc
ttgctgttgct). Research was approved by the Internal Review
Board of the Department of Medical Sciences, University
of Torino. A written informed consent for publication was
obtained from members participating in the study.
Genetic analyses
Genomic DNA was extracted from peripheral blood
(Qiagen, Hilden, Germany) following the manufacturer
instructions.
Exome capture was performed with Agilent SureSelect
Human All Exon kit (Agilent Technologies, Santa Clara,
CA, USA) according to the manufacturer protocols.
Sequencing was performed on an Illumina HiSeq 2000
machine using a standard pair-end read sequencing
protocol (Illumina, San Diego, CA, USA) to generate se-
quencing reads of up to 90 cycles. We applied default
settings in the Illumina pipeline to call bases from raw
images, generating raw sequencing reads in the format
of fastq files. We subsequently applied two independent
analysis methods to perform alignment, variant calling
and annotation. Pipeline 1 (P1) aligned fastq files to the
human reference genome (UCSC hg19) with BWA then
used Genome Analysis Tool Kit (version 1.4) to call
variants, followed by utilizing Annovar and SnpEff for
the variant functional annotation step. Pipeline 2 (P2)
mapped fastq files to the human reference genome (UCSC
hg19) with SOAP (version 2.21) and used SOAPsnp
(version 1.05) for single nucleotide variant (SNV) detec-
tion, and used GATK for small insertion-deletion (indel)
detection, followed by BGI self-developed programs to
perform variant functional annotation.
We excluded variants that were: 1) out of exonic re-
gions, 2) synonymous changes and 3) with minor allele
frequency (MAF) > 0.5% in either the 1000 Genomes
Project (http://www.1000genomes.org/), the NHLBI Ex-
ome Sequencing Project (ESP6500; http://evs.gs.washing-
ton.edu/EVS/), or our internal exome datasets. Variants
near splicing donor/recipient sites and frameshift indels
were given particular attention as they could cause patho-
genic changes like exon-skipping or frameshifts. We
filtered variants based on 1) evolutionary conservation,
ie variants of PhyloP value <0.95 were considered to be
in non-conserved regions thus discarded; 2) prediction
of pathogenicity by PolyPhen and SIFT software.Validation of the mutation was performed by Sanger
sequencing in all members of the family with primers
designed to amplify the exon 17 region of SETX (Refer-
ence sequence: NM_015046.5)(5′-tgggaactaattttccttct-
cattg and 5′-agcctggaagacagagcaagact).
AFG3L2 mutation analysis and functional assay
Clustal omega (http://www.clustal.org/omega/) was used for
evolutionary conservation analysis. AFG3L2 (NM_006796)
exon 4 was amplified and sequenced accordingly to previous
published protocol [7]. For the yeast complementation
assay a combination of human wild-type or mutant
human AFG3L2 was expressed with or without wild-
type paraplegin in a previously generated yeast strain
Δyta10Δyta1.[5] AFG3L2 was mutagenized in the yeast
expression constructs using the QuickChange XL Site-
Directed Mutagenesis Kit (Stratagene, LaJolla, CA). Yeast
cells were grown according to standard procedures at 30°C
in YP medium containing 2% (w/v) dextrose (glucose)
(YPD). For testing the respiratory activity, yeast cells
were grown at 30°C on solid state or in the liquid YP
media containing 3% (w/v) glycerol as the sole carbon
source (YPG). Experiments were repeated three times
with overlapping results.
Results
Genetic analysis
Whole exome sequencing on three family members (II.1,
II.3, II.7) was performed with at least 57X coverage
depth (Additional file 1: Table S1 and S2). Two analysis
pipelines were used for each exome: P1 called ~45,000
SNVs and ~7,500 indels, P2 ~ 74,000 SNVs and ~5,000
indels. Further analysis was restricted to variants occur-
ring in coding regions or at splicing sites, reducing SNVs
to ~17,000 and indels to ~700 in P1, and ~17,000 SNVs
and ~630 indels in P2 (Additional file 1: Table S1).
We initially analyzed the coding region of known
ataxia causing genes assuming an autosomal recessive or
dominant model of inheritance. We retained only rare
(MAF < 0.5% in 1000 Genomes Project, the ESP6500 and
CAG/BGI internal exome datasets) non-synonymous
variants or splice site variants. A single homozygous C
to T variant on chr 9:135,163,655 causing a c.6292C > T
(p.Arg2098*) in the SETX gene (NM_015046.5, OMIM
*608465, http://www.omim.org/) was left after both P1
and P2 lists (Additional file 1: Table S3). This homozy-
gous mutation was confirmed by Sanger sequencing in
all affected individuals (Figure 1B), and haplotype ana-
lysis showed that it was derived from a common ances-
tor (Figure 1A). Although consanguinity in patients
parents was denied, they were both born in a small
village in Sicily increasing the likelihood they were
consanguineous. The three sisters (II.1, II.2 and II.7)
also shared the c.346G > A variant in the AFG3L2 gene
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file 1: Table S4). AFG3L2 encodes for a subunit of the
hetero-oligomeric m-AAA protease (ATPases associated
with various cellular activities), a component of the mito-
chondrial ATP-dependent metalloprotease located on the
inner mitochondrial membrane, and its mutations in
heterozygosis are associated with Spinocerebellar ataxia
type 28 (SCA28) [8].
Segregation analysis showed that this variant was
present also in the third affected sister II.3, but it was
absent in II.4, II.5 and II.6 (Figure 1A). This substitution
is not reported as validated polymorphism in Human
variation resources (dbSNP(138), 1000 genomes, EVS,
ExAC or HapMap databases), hit a highly conserved
residue through all vertebrates (Figure 1C), it was pre-
dicted to be highly pathogenic by Mutation taster soft-
ware (probability: 0.999; www.mutationtaster.org/) and
to affect protein function with a score of 0.03 by SIFT
Alignment (Median sequence conservation: 3.34; sift.
jcvi.org/). The substitution is between the two mito-
chondrial transmembrane domains of AFG3L2.
We introduced the c.346G > A (p.Gly116Arg) muta-
tion in the human full length AFG3L2 cDNA. Expression
in Δyta10Δyta12 cells did not restore mitochondrial re-
spiratory activity as shown by the inhibition of growth
on glycerol-containing media. Co-expression of SPG7
with AFG3L2G116R in Δyta10Δyta12 cells substantially
restored respiratory growth to normal levels (Figure 1D).
Clinical findings
Between 9 and 12 yrs, three subjects from family ATA-2-
TO (II.1, II.2, II.3 in Figure 1A) presented with unsteadi-
ness and difficulties in walking accompanied by a large
spectrum of involuntary movements such as myoclonic
jerks at arms and hands, and/or choreic movements and
facial dyskinesia. Myoclonic jerks were spontaneous and
stimulus-insensitive, of small amplitude and arrhythmic.
They were present at rest, on sustained posture and on
action, involved proximal and distal segments of the upper
limbs, and the perioral region. They attenuated over the
course of the disease without disappearing.
Basal electroencephalography (EEG) and polygraphic
EEG-EMG were normal and disease progression was
slow. Patients developed truncal and limb ataxia with a
progressive sensory-motor neuropathy that led them to
difficulty walk without help after 5–8 years of disease.
All patients were wheelchair-bound before 30 yrs.
Further signs included areflexia, distal absence of
vibratory sensibility of the knees, and altered Somato-
sensory Evoked Potential.
Oculomotor abnormalities included nystagmus in all
directions, hypometric saccades, saccadic pursuit, but no
overt oculomotor apraxia. A mild limitation of the bi-
lateral horizontal gaze was observed in II.3 (convergentstrabismus) and a mild eyelid ptosis in II.1 was present
after more than 30 years of disease.
One patient (II.3) showed a borderline intellectual dis-
ability (IQ = 77).
At last examination (~40 yrs of disease duration, sum-
mary in Table 1), subjects presented with severe ataxia.
Notably, all cases had an early menopause.
Skeletal abnormalities included a kyphoscoliosis (3/3)
whereas pes cavus was not present.
Serum alpha-fetoprotein, obtained only at the last
examination, was increased (Table 1).
Neuroradiology showed a marked cerebellar atrophy
of hemispheres and vermis (Additional file 2: Figure S1).
Parents were reported healthy. The mother died at age
37 from pregnancy related complications, the father
living at age 72 has been reported as unaffected, but he
was unavailable for clinical examination.
Patient II.7
All siblings of the three affected individuals underwent a
neurological investigation and did not show any neuro-
logic phenotype except II.7. She reported occasional ex-
perience of imbalance, mainly after fatigue or stress at
36 yrs. At 42 yrs, neurological examination showed the
presence of sporadic spontaneous myoclonus at proximal
upper limbs and at the perioral district, confirmed by elec-
tromyography. Hyperreflexia at upper limbs, hyperactive
patellar and ankle reflexes with a bilateral foot clonus and
mild hypertonia at lower limbs with a weak Babinski sign,
suggested a mild pyramidal involvement. No cerebellar
ataxia, oculomotor abnormalities, and sensory deficits
were present. MRI was not available.
Discussion
Diagnosis for rare inherited ataxias is hampered by the
clinical overlap of heterogeneous disorders, and routine
tests are often limited to repeat expansions, with rarer
genes interrogated only in a research based setting. Tar-
geted resequencing and exome sequencing are rapidly
changing this approach demonstrating their utility as a
diagnostic tool [9].
Ataxia and sensory-motor neuropathy are typical
symptoms of AOA2 that may be complicated by add-
itional movement disorders during the disease course.
Chorea/choreoathetosis, facial dyskinesia, dystonia, head/
postural tremor are described in 14% of AOA2 patients,
but they were never reported at onset [10-12]. Myoclonus
is described in only one AOA2 case [13].
We studied an atypical form of AOA2 with involun-
tary movements/myoclonus at onset shared by three sis-
ters. None had oculomotor apraxia (OMA), reported in
half of the AOA2 cases. However, all had hypometric
saccades with a staircase pattern, a sign recently sug-
gested as more reliable for OMA [14].
Table 1 Neurological and biochemical features of AOA2 patients
Patients II.1 II.2 II.3
Sex/age F/51 F/49 F/44
Age at onset of gait ataxia 12 9 12
Disease duration (years) 39 40 32
Interval onset-wheelchair (years) 21 28 23
Initial symptom Chorea/myoclonia Chorea/myoclonia Chorea/myoclonia
Oculomotor anomalies
OMA - - -
Hypometric saccades +++ +++ +++
Saccadic pursuit + (33 yrs.)* + (34 yrs.)* + (26 yrs.)*
Strabismus - - +
Ptosis +(39 yrs) - -
Pyramidal signs
Plantar Reflex - Extension -
Involuntary movements
Head/hand tremor ++(24 yrs.) ++(30 yrs.) ++(32 yrs.)
Myoclonus UL, LL UL, LL UL, LL
Dystonia +(33 yrs.) +(40 yrs.) -
Facial Dyskinesia/ Choreic movements + + +
Other Extra-pyramidal signs Bradikynesia/hypomimia Bradikynesia/hypomimia Bradikynesia/hypomimia
Reflexa Absent UL/LL Absent UL/LL Absent UL/LL
Peripheral neuropathy
Distal amiotrophy (UL, LL) +++ +++ +++
Deep sensory loss +++ +++ +++
Sensory loss +++ - -
Pain and light touch DecreasedUL;absent LL Decreased UL;absent LL Decreased UL; loss LL
Sensory motor neuropathy +++ +++ +++
Others
SARA Score 27/40 27/40 23/40
IQ (WAISS) 93 (102/83) 87 (86/89) 77 (78/78)
Progression of disability 17;21;36** 17;21;37** 17;21;38**
Pes cavus - - -
Kyphoscoliosis +++ +++ +++
Early menopause (yrs) 33 32 34
Brain MRI
Vermian Atrophy +++ +++ +++
Brainstem atrophy - - ++
Biochemistry
AFP, ng/ml (normal level <7 ng/ml) 19 61 37
Cholesterol norm norm norm
Genetics
SETX homozygous mutation c.6292C > T (p.Arg2098*) c.6292C > T (p.Arg2098*) c.6292C > T (p.Arg2098*)
AFG3L2 heterozygous mutation c.346G > A (p.Gly116Arg) c.346G > A (p.Gly116Arg) c.346G > A (p.Gly116Arg)
Legend: − None; + Mild; ++ Moderate; +++ Severe; norm: normal; na: not available; *disease duration; UL Upper Limbs; LL Lower Limbs.
**Progression of disability indicates gait possible with one help; with a double help; wheelchair bounded. WAISS Weschler adult intelligence Scale Score; total IQ,
and verbal/non verbal IQ (among brackets) are indicated.
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vergent strabismus in the left eye occurred in II-3 after
26 yrs. of disease (12-38% of AOA2 patients) [10,11].
Ptosis, never reported in AOA2, may be a late sign of
disease, and appeared unilaterally in the eldest patient
at 51 yrs. Further uncommon features included a mild
cognitive impairment in II.3 [11]. Skeletal abnormalities
included a kyphoscoliosis (3/3) never reported in AOA2,
whereas pes cavus, a finding present in almost all reported
AOA2 cases was not present [10,11].
We noted that all three sisters presented a premature
menopause between 32 and 34 yrs, a feature already oc-
casionally reported in AOA2 [15,16]. This may suggest
an association between SETX mutations and premature
ovarian failure/premature menopause that deserves
further studies.
Among the other four siblings, II.7 showed spontan-
eous mild myoclonus and hyperreflexia at upper and
lower limbs.
Exome sequencing identified a homozygous c.6292C > T
(p.Arg2098*) mutation in this gene. This same mutation
in homozygosis had already been described in six AOA2
Tunisian patients (Family E) [17], who showed a typical
form of disease without involuntary movements/myoclo-
nus. This finding suggested that a second genetic deter-
minant may have combined its effect with the SETX
mutation to give the atypical phenotype in our family.
Exome data also revealed the c.346G >A (p.Gly116Arg)
missense change in AFG3L2, encoding for a mitochondrial
protease. In the inner membrane of human mitochondria
two different functionally active m-AAA isoenzymes are
present: a homo-oligomeric AFG3L2 complex and a
hetero-oligomeric complex where AFG3L2 subunits as-
semble with paraplegin. Mutations in this gene cause both
an autosomal dominant spinocerebellar ataxia (SCA28)
characterized by ophtalmoplegia/ptosis and oculomotor
alterations [7,8] or an autosomal recessive form of early
onset spastic ataxia with neuropathy and myoclonic epi-
lepsy (SPAX5) [18].
Yeast experiments demonstrated that only homo-
oligomeric m-AAA protease complexes composed by
AFG3L2G116R subunits are functionally impaired. We
concluded that AFG3L2G116R is likely pathogenic, but
behaves differently from AFG3L2 mutations causing
SCA28, that fail to be rescued by paraplegin co-expression
[8]. AFG3L2 mutations reported in the literature mainly
cluster in the protease C-terminal domain [7,8,19].
Localization of p.Gly116Arg at the N-terminal portion
of the protein, suggests a different effect on the protein
that may lead to a so far never reported phenotype.
Indeed, p.Gly116Arg was present in the three affected
sisters and II.7 only. The latter had subclinical myoclo-
nus at age 41. All four siblings without AOA2 (including
II.7) were carriers of the c.6292C > T mutation in SETX.Conclusion
Using exome sequencing, we identified an atypical form
of AOA2 with myoclonus at onset associated with the
c.6292C > T (p.Arg2098*) homozygous mutation. We
hypothesize that the combination of AOA2 with the
c.346G > A (p.Gly116Arg) mutation in AFG3L2, is re-
sponsible for the variant phenotype seen in three
patients. The p.Gly116Arg variant in AFG3L2 may be a
candidate for myoclonus, but we cannot exclude this is
an initial symptom that will evolve into a more complex
phenotype.
We suggest that variant phenotypes may be due to the
combined effect of different mutated genes associated to
ataxia or related disorders, that will become more appar-
ent as the costs of exome sequencing progressively will
reduce, amplifying its diagnostics use, and meanwhile
proposing significant challenges in the interpretation of
the data.
Additional files
Additional file 1: Table S1. Exome sequencing summary statistics.
Table S2. Rare variants candidate list from two independent analysis
pipelines base on autosomal recessive model of inheritance and multiple
steps of filtering. Table S3. Homozygous variant shared by both patients
before filtering on allele frequency and variant annotation. Table S4.
Heterozygous variant shared by both patients before filtering on allele
frequency and variant annotation.
Additional file 2: Figure S1. MRI of AOA2 patients. Coronal (A and B)
and sagittal (C and D) T1-weighted brain resonance magnetic imaging
slices. Panel A and B represent patient II.1 at 41 yrs (29 yrs of disease duration),
and panels C and D represent II.3 at 34 yrs (22 yrs of disease duration).
A marked cerebellar hemispheric and vermian atrophy was present in
both patients (arrow).
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